Kalaris director granted options on 9,000 shares

Kalaris Therapeutics director Jovan-Embiricos Morana received a stock option grant covering 9,000 shares of common stock.

Accepted by SEC EDGAR 06/04/2026 - 04:38 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kalaris Therapeutics director Jovan-Embiricos Morana received a stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.7200 per share and expires on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholders’ meeting, subject to continued service. Following this grant, Morana holds options to purchase 9,000 shares directly.

Insider Trade Summary

Grant/Award: 9,000 shares

Grant/Award 1 txn

Insider Jovan-Embiricos Morana

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 9,000 options (Direct)

Footnotes (1)

1. F1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Key Figures

Option grant size: 9,000 shares Exercise price: $4.7200 per share Expiration date: June 2, 2036 +2 more

5 metrics

Option grant size 9,000 shares Stock Option (Right to Buy) granted to director

Exercise price $4.7200 per share Exercise price for 9,000-share option grant

Expiration date June 2, 2036 Option term end date

Post-grant option holdings 9,000 shares Total options held directly after transaction

Vesting date trigger June 3, 2027 Earlier of this date or 2027 annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, vest in full, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.7200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"shares underlying the option are scheduled to vest in full"

expiration date financial

"expiration_date: 2036-06-02T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kalaris Therapeutics (KLRS) disclose in this Form 4?

Kalaris Therapeutics reported a stock option grant to director Jovan-Embiricos Morana for 9,000 shares. The option has an exercise price of $4.7200 per share and represents compensation rather than an open-market stock purchase or sale.

How many KLRS shares are covered by the new option grant?

The new stock option grant covers 9,000 shares of Kalaris Therapeutics common stock. These shares are underlying the option and can be acquired by exercising it at the stated price, subject to the vesting schedule and expiration terms in the grant.

What is the exercise price and expiration date of the KLRS option grant?

The stock option granted to the director has an exercise price of $4.7200 per share and expires on June 2, 2036. These terms define the cost to acquire shares and the final date by which the option must be exercised.

When do the KLRS stock options granted to the director vest?

The 9,000 shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics’ 2027 annual stockholders’ meeting. Vesting is conditioned on the director’s continued service with the company.

Is this KLRS Form 4 an open-market buy or sell of shares?

No, this Form 4 reports a stock option grant as compensation to a director, not an open-market trade. The transaction is coded as a grant or award acquisition, with the director receiving options rather than immediately buying or selling common shares.

How many KLRS options does the director hold after this transaction?

After this transaction, the director holds stock options to purchase 9,000 shares of Kalaris Therapeutics common stock directly. This reflects the total derivative holdings reported in connection with this grant in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jovan-Embiricos Morana

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.72	06/03/2026		A		9,000		(1)	06/02/2036	Common Stock	9,000	$0	9,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brett Hagen, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)